Literature DB >> 6311408

Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells.

A Ramu, D Glaubiger, I T Magrath, A Joshi.   

Abstract

We have studied the structural order of the lipid phase of plasma membranes from P388 murine leukemia cells and from a Doxorubicin-resistant subline, P388/ADR, using electron spin resonance spectroscopy and fluorescence depolarization measurements. Measurements of the order parameter, S, following incubation of cells from both lines with the N-oxyl-4'-4'-dimethyloxazolidine derivative of 5-ketostearic acid show higher values for the resistant cells at all temperatures where S was measured (4-37 degrees). Fluorescence depolarization measurements following incubation of the cells, or cell fractions, with 1,6-diphenylhexatriene indicate more restricted motion of the probe in resistant cells. These measurements also show increased amounts of cytoplasmic lipid in the resistant cells. The higher degree of structural order in the lipid phase of the plasma membranes of P388/ADR cells and their larger intracellular lipid content may account for the decreased rate of intracellular accumulation of anthracycline drugs (and other compounds) seen in these cells and, in part, for their relative resistance to the cytotoxic effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids.

Authors:  Vijay Raghavan; Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Masayoshi Yamada; Megan Morisada; Vinod Labhasetwar
Journal:  Langmuir       Date:  2015-10-15       Impact factor: 3.882

3.  Effect of hyperthermia and thermochemotherapy on primary and metastatic tumour cells of AKR lymphoma.

Authors:  G Klorin; A Siegal; B Bar-Shira-Maymon; O Klein; J Leibovici
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

Review 4.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 5.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Sensitivity to thermochemotherapy of AKR lymphoma and B16 melanoma variants of malignancy.

Authors:  J Leibovici; G Klorin; M Huszar; S Hoenig; O Klein; M Michowitz; A Pinchassov
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

7.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

Authors:  G Scambia; F O Ranelletti; P B Panici; R De Vincenzo; G Bonanno; G Ferrandina; M Piantelli; S Bussa; C Rumi; M Cianfriglia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Phorbol ester selectively stimulates the phospholipase D-mediated hydrolysis of phosphatidylethanolamine in multidrug-resistant MCF-7 human breast carcinoma cells.

Authors:  Z Kiss; M Tomono; W B Anderson
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

10.  Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.

Authors:  B J Foster; K R Grotzinger; W M McKoy; L V Rubinstein; T C Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.